Novavax, Inc. (NASDAQ:NVAX) Shares Sold by Federated Hermes Inc.

Federated Hermes Inc. trimmed its holdings in shares of Novavax, Inc. (NASDAQ:NVAX) by 88.6% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 52,713 shares of the biopharmaceutical company’s stock after selling 409,114 shares during the period. Federated Hermes Inc.’s holdings in Novavax were worth $253,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. boosted its position in shares of Novavax by 467.0% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 13,743 shares of the biopharmaceutical company’s stock worth $66,000 after buying an additional 11,319 shares during the period. Fox Run Management L.L.C. purchased a new position in Novavax in the 3rd quarter worth approximately $72,000. Hodges Capital Management Inc. purchased a new position in Novavax in the 3rd quarter worth approximately $72,000. Nomura Holdings Inc. acquired a new stake in Novavax in the third quarter valued at approximately $74,000. Finally, Raymond James Financial Services Advisors Inc. purchased a new stake in shares of Novavax during the third quarter valued at approximately $76,000. 53.04% of the stock is currently owned by institutional investors and hedge funds.

Novavax Stock Performance

NASDAQ:NVAX opened at $4.93 on Monday. The stock has a market cap of $692.17 million, a price-to-earnings ratio of -0.89 and a beta of 1.63. Novavax, Inc. has a one year low of $3.53 and a one year high of $11.36. The business’s 50-day simple moving average is $4.71 and its 200 day simple moving average is $5.01.

Novavax (NASDAQ:NVAX) last posted its quarterly earnings data on Wednesday, February 28th. The biopharmaceutical company reported ($1.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by ($0.95). The business had revenue of $291.34 million during the quarter, compared to the consensus estimate of $310.96 million. The firm’s revenue was down 18.5% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($2.28) EPS. On average, equities research analysts predict that Novavax, Inc. will post -0.82 EPS for the current year.

Wall Street Analyst Weigh In

Separately, HC Wainwright lowered their price target on shares of Novavax from $35.00 to $19.00 and set a “buy” rating for the company in a report on Friday, March 1st.

About Novavax

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.